Core Viewpoint - CICC initiates coverage of Rebio Biotech-B (06938) with an "outperform" rating, setting a target price of HKD 100.0, indicating a potential upside of 44.9% from the current stock price [1][9]. Company Overview - Rebio is a global leader in small RNA drug development, possessing a proven and mature small RNA drug development platform [2][10]. - Since its establishment in 2007, the company has developed the GalNAc liver-targeting RiboGalSTAR platform and is expanding from liver-targeting to extrahepatic targeting [2][10]. - The company continuously iterates chemical modifications to enhance target specificity and sequence compatibility while reducing off-target effects, thereby improving efficacy and safety [2][10]. - As of the end of 2025, Rebio holds 473 patents and patent applications across major jurisdictions, establishing a comprehensive intellectual property portfolio [2][10]. - The company's R&D platform integrates the entire technical chain, ensuring efficiency in pipeline advancement from CMC production and early research to commercialization [2][10]. Clinical Assets - Rebio is one of the Chinese small RNA companies with the most clinical assets, having seven siRNA candidates in clinical stages as of the end of 2025, with four in Phase II [3][11]. - Key assets include RBD4059 (FXI), RBD5044 (ApoC3), and RBD1016 (HBV) [3][11]. - RBD4059 is the world's first and fastest clinical siRNA drug for treating thrombotic diseases, expected to enter Phase IIb clinical trials in 2026 [3][11]. - RBD5044 is the second siRNA targeting ApoC3 to enter clinical stages, following Arrowhead [3][11]. - RBD1016 is currently being evaluated for its drugability in HBV [3][11]. Market Perspective - The primary market concern is the drugability of FXI inhibitors; however, CICC believes that FXI inhibitors have demonstrated drugability in indications such as stroke and post-knee replacement surgery [4][12]. - FXI siRNA is expected to tackle atrial fibrillation indications due to its higher target inhibition rate [4][12]. Potential Catalysts - The industry is mapping data for FXI inhibitors and ApoC3 siRNA, with multiple Rebio small RNA drugs entering Phase II clinical trials and data readouts expected [5][13].

Core Viewpoint - The approval of the IND application for CS2009 by the FDA marks a significant advancement in the global development of this innovative immunotherapy for advanced solid tumors [1] Group 1: Company Developments - 基石药业's stock rose over 5% in early trading, currently at 6.19 HKD with a trading volume of 26.55 million HKD [1] - The company announced that its core asset CS2009, a tri-specific antibody targeting PD-1/VEGF/CTLA-4, has received FDA approval for its Phase II clinical trial application [1] Group 2: Clinical Trial Insights - Preliminary data from the Phase I clinical study of CS2009 will be presented at the 2025 European Society for Medical Oncology (ESMO) annual meeting, indicating good safety and tolerability, along with positive anti-tumor activity data [1] - Additional data from both Phase I and Phase II clinical studies is expected to be released at the upcoming American Society of Clinical Oncology (ASCO) and ESMO meetings this year [1]

Core Viewpoint - The approval of the IND application for CS2009 by the FDA marks a significant advancement in the global development of this innovative immunotherapy for advanced solid tumors [1][2] Group 1: Clinical Trial Details - CS2009 is a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, and is set to undergo a Phase II clinical trial for advanced solid tumors [1] - The Phase II global multi-center clinical trial is actively recruiting in Australia and China, encompassing 15 monotherapy/combo therapy cohorts and 9 solid tumor indications, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), triple-negative breast cancer (TNBC), extensive-stage small cell lung cancer (ES-SCLC), and platinum-resistant ovarian cancer (PROC) [1] Group 2: Preliminary Data and Future Expectations - Preliminary data from the Phase I clinical study of CS2009 has shown good safety and tolerability, with positive anti-tumor activity results expected to be presented at the upcoming American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) meetings [1] - The CEO of the company expressed satisfaction with the efficient progress of the Phase II clinical trial and highlighted the positive communication with the FDA regarding the drug's performance in the Phase I trial [2]

Core Viewpoint - CICC initiates coverage on RiboBio-B (06938) with an "outperform" rating, setting a target price of HKD 100.0, indicating a 44.9% upside potential from the current stock price [1] Group 1: Company Overview - RiboBio is a global leader in small RNA drug development, possessing a proven and mature small RNA drug development platform [1] - Since its establishment in 2007, the company has developed the GalNAc liver-targeting RiboGalSTAR platform and is expanding from liver-targeting to extrahepatic targeting [1] - The company continuously iterates chemical modifications to enhance target specificity and sequence compatibility while reducing off-target effects, thereby improving efficacy and safety [1] - As of the end of 2025, RiboBio holds 473 patents and patent applications across major jurisdictions, establishing a comprehensive intellectual property portfolio [1] - The company's R&D platform integrates the entire technology chain, ensuring efficiency in pipeline advancement from CMC production and early research to commercialization [1] Group 2: Clinical Assets - RiboBio is one of the Chinese small RNA companies with the most clinical assets, having 7 siRNA candidates in clinical stages as of the end of 2025, with 4 in Phase II [2] - Core assets include RBD4059 (FXI), RBD5044 (ApoC3), and RBD1016 (HBV) [2] - RBD4059 is the world's first and fastest clinical FXI siRNA drug for treating thrombotic diseases, expected to enter Phase IIb clinical trials in 2026 [2] - RBD5044 is the second siRNA targeting ApoC3 to enter clinical stages, following Arrowhead [2] - RBD1016 is currently being evaluated for its drugability in HBV [2] Group 3: Market Perspective - The main difference between the firm and the market is the belief in the drugability of FXI inhibitors, particularly for conditions like stroke and post-knee replacement surgery, which have validated drugability [3] - FXI siRNA is expected to tackle atrial fibrillation indications due to its higher target inhibition rate [3] Group 4: Potential Catalysts - Potential catalysts include data mapping for FXI inhibitors and ApoC3 siRNA, as well as the initiation of Phase II clinical trials and data readouts for multiple small RNA drugs from RiboBio [4]

Core Viewpoint - The article discusses the significant decline in the stock prices of ten high-issue-price stocks in the A-share market, with seven of them falling below their issue prices, highlighting the risks associated with high valuations and market sentiment shifts [1][22]. Group 1: Stock Performance - Among the ten stocks, only Stone Technology, Naxin Micro, and BeiGene remain above their issue prices as of mid-February 2026 [6][8]. - The maximum decline from issue prices includes: - CanSino down 69.15% - Wanrun New Energy down 58.54% - Huabao New Energy down 54.93% - Yiqiao Shenzhou down 42.22% - Hemai down 32.82% - Foxit Software down 22.17% - Suocheng Technology down 12.83% [10]. - CanSino experienced a dramatic drop of 93% from its peak price of 797.20 yuan to 63.90 yuan [11][19]. Group 2: Company Backgrounds - Hemai, the highest issue price stock at 557.80 yuan, faced a significant decline after reaching a peak of 1877.43 yuan [12]. - Wanrun New Energy, listed at 299.88 yuan, never reached its issue price after its first day of trading [15]. - Yiqiao Shenzhou, with an issue price of 292.92 yuan, peaked at 353.83 yuan before falling to 73.38 yuan [16]. - CanSino, a COVID-19 vaccine stock, was listed at 209.71 yuan and peaked at 797.20 yuan before its decline [17]. Group 3: Market Conditions and Trends - The high issue prices were driven by market enthusiasm for sectors like hard technology, new energy, and biomedicine during the registration reform period from 2020 to 2023 [5][4]. - The overall market sentiment has shifted, leading to a decline in these stocks as the initial excitement waned [22]. - The article notes that the current new stock market shows a stark contrast, with a recent increase in participation and initial gains, but also warns of accumulating risks [24][26]. Group 4: Investment Implications - The high issue prices and P/E ratios of these stocks are no longer guarantees of company strength, but rather potential warning signs of investment risk [28]. - The article emphasizes that the era of easy profits from new stock subscriptions has ended, requiring more thorough research and disciplined investment strategies [27].

Core Viewpoint - Moderna has engaged in further discussions with regulatory authorities and announced that the FDA will accept its application for the market approval of an mRNA-based influenza vaccine after initially rejecting it due to flaws in the study design [1] Group 1 - The FDA initially rejected Moderna's application for the new influenza vaccine, citing defects in the study design [1] - Following subsequent communications, the FDA reversed its decision and agreed to initiate the review process for the vaccine [1]

Core Viewpoint - Tianyan Pharmaceutical has announced its business progress and annual goals for 2026, including multiple clinical data releases and research plans [1]. Recent Events - In Q1 2026, the company plans to release updated research data from a 1b/2 phase study of muzastotug (ADG126) combined with pembrolizumab for patients with third-line or higher microsatellite stable colorectal cancer (MSS CRC), including results from the 10 mg/kg dose group (41 patients) and the 20 mg/kg dose group (26 patients) [1]. - Concurrently, the company will share clinical research results in collaboration with Roche, evaluating the efficacy and safety of muzastotug combined with atezolizumab and bevacizumab for first-line treatment of hepatocellular carcinoma (HCC) [1]. - New data will be disclosed, including preliminary data from a new patient cohort using muzastotug combined with pembrolizumab and standard treatment (fruquintinib) for MSS CRC, as well as early progress from a phase 2 trial of neoadjuvant treatment for colorectal cancer led by the National University Hospital of Singapore [1]. Product Development Progress - Patient enrollment is expected to be completed for the randomized phase 2 dose optimization study of muzastotug, which aims to determine the optimal dosing regimen for phase 3 clinical trials [2]. - The company will continue to advance collaboration and licensing agreements, including projects with partners such as Sanofi and Third Arc Bio [2]. Financial Status - As of December 31, 2025, the company reported cash and cash equivalents of $74.5 million (unaudited), which is expected to support operations until the end of 2027, providing funding assurance for the aforementioned plans [3].

Core Insights - The company, Weili Zhibo, focuses on three core technology platforms targeting tumors and autoimmune diseases, including LeadsBody, X-body, and TOPiKinetics [1] - LBL-024 has a broad indication layout with 12 indications and 9 ongoing clinical trials, including a pivotal study expected to submit a BLA by Q3 2026 [1] - LBL-034 is currently in a Phase II study with promising safety and efficacy data across four patient populations, including those with relapsed refractory multiple myeloma [2] Company Developments - The company has established seamless capabilities in early research, translational medicine, clinical development, CMC, and business expansion [1] - Two autoimmune disease products have achieved overseas collaboration, with LBL-047 having enrolled its first patient and LBL-051 planning to submit a clinical application to the FDA in Q1 2026 [2] Financial Projections - Revenue forecasts for 2025-2027 are estimated at 175.0 million, 196.0 million, and 200.8 million, reflecting year-on-year growth of -/12.0%/+2.4% [2] - The current stock price corresponds to PS ratios of 62, 55, and 54 for the respective years [2] - The company is expected to experience significant clinical data catalysts in 2026, with a potential commercialization inflection point in 2027 [2]

Group 1 - Core viewpoint: Sinovac Biotech Ltd. (SVA) is facing significant challenges, including a potential delisting from NASDAQ due to failure to submit its 2024 annual report within the extended deadline [1] - The company plans to apply for a hearing to contest the delisting decision, which is a critical event affecting investor expectations regarding stock liquidity and corporate governance stability [1] - The outcome of a court hearing scheduled for late April to early May 2026 regarding shareholder meeting disputes may indirectly impact the company's governance structure and operational stability [1] Group 2 - In November 2025, Sinovac Biotech signed a vaccine supply contract worth over $700 million with the Brazilian Ministry of Health, aiming to provide varicella and rabies vaccines over the next decade [1] - The execution of this contract, including production delivery and revenue recognition, will be a key indicator of the company's ability to recover its overseas business [1]

格隆汇2月16日丨复宏汉霖(02696.HK)宣布，近日，公司自主研发的HLX15-SC(重组抗CD38全人单克隆 抗体注射液－皮下注射)(「HLX15-SC」)用于多发性骨髓瘤治疗的1期临床试验申请(IND)获美国食品药 品管理局(FDA)批准。 ...